Company profile
Cartesian Therapeutics, Inc.
NASDAQ: RNAC · Healthcare · Biotechnology
#947 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
40DFH 22DQ 75GM 13SS 58
v0.1 · 65/100 weight · provisional
↑ disclosure history, filing timeliness · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$1.8M
Rev growth YoY (TTM)
-94.8%
Net income (FY)
-$130.3M
Employees
75
as of 2026-08-13
Market cap
$254.9M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$400.0k$400.0k2025
Net income-$130.3M-$130.3M2025
Operating income-$143.4M-$143.4M2025
Total assets$296.4M$296.4M2025
Liabilities$422.7M$422.7M2025
Equity-$126.2M-$126.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Operating100%
By geography
Not disclosed.
The read
What is Cartesian Therapeutics, Inc.’s revenue?
Cartesian Therapeutics, Inc. booked $400.0k in FY2025 revenue, contracting 99% year over year — among the slowest-growing Healthcare companies we track, at a -32575.5% net margin.
Peers · Healthcare
Aequus Pharmaceuticals Inc.——Amarantus BioScience Holdings, Inc.——MediciNova, Inc.41DiBio, Inc.48DNeurogenesis, Inc.——Lyra Therapeutics, Inc.30DNeighbors
Frederick →Key facts
CEOCarsten Brunn
SectorHealthcare
IndustryBiotechnology
HeadquartersFrederick, MD
ExchangeNASDAQ: RNAC
Employees75
IPO date2016-06-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.